BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38889943)

  • 1. Risk-reducing salpingo-oophorectomy among diverse patients with
    Lamacki AJ; Spychalska S; Maga T; Balay L; Lugo Santiago N; Hoskins K; Richardson K; Class QA; MacLaughlan David S
    BMJ Open; 2024 Jun; 14(6):e082608. PubMed ID: 38889943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
    Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
    Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
    Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
    Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
    Chen Y; Bancroft E; Ashley S; Arden-Jones A; Thomas S; Shanley S; Saya S; ; Wakeling E; Eeles R
    Fam Cancer; 2014 Jun; 13(2):197-203. PubMed ID: 24389956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies.
    Hickey I; Jha S; Wyld L
    Gynecol Oncol; 2021 Mar; 160(3):763-770. PubMed ID: 33317909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
    Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    Crosbie EJ; Flaum N; Harkness EF; Clayton RD; Holland C; Martin-Hirsch P; Wood N; Keating P; Woodward ER; Lalloo F; Donnai P; Edmondson RJ; Evans DG
    Int J Cancer; 2021 Mar; 148(5):1155-1163. PubMed ID: 33152107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Solsky I; Chen J; Rebbeck TR
    Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.
    Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
    Menopause; 2020 Jan; 27(1):26-32. PubMed ID: 31613831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
    JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone health after RRBSO among
    do Valle HA; Kaur P; Kwon JS; Cheifetz R; Dawson L; Hanley GE
    J Gynecol Oncol; 2022 Jul; 33(4):e51. PubMed ID: 35557034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
    Kershaw V; Hickey I; Wyld L; Jha S
    Eur J Obstet Gynecol Reprod Biol; 2021 Oct; 265():7-17. PubMed ID: 34416580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral Salpingo-oophorectomy and Breast Cancer Risk for
    Conduit C; Milne RL; Friedlander ML; Phillips KA
    Cancer Prev Res (Phila); 2021 Nov; 14(11):983-994. PubMed ID: 34348913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
    Lynce F; Schlam I; Geng X; Peshkin BN; Friedman S; Dutil J; Nahleh Z; Campos C; Ricker C; Rodriguez P; Denduluri N; Ahn J; Isaacs C; Graves KD
    J Genet Couns; 2021 Apr; 30(2):383-393. PubMed ID: 33010199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
    Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
    Menopause; 2020 Jan; 27(1):20-25. PubMed ID: 31567874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
    Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA
    Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
    Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
    Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
    Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.